ELVN NASDAQ
Enliven Therapeutics, Inc.
1W: +7.2%
1M: -7.3%
3M: -22.8%
YTD: +167.0%
1Y: +101.9%
3Y: +226.9%
5Y: +175.9%
$43.69
+2.20 (+5.30%)
After Hours: $43.28 (-0.41, -0.93%)
Weekly Expected Move ±6.8%
$36
$39
$42
$44
$47
Credit Risk of going bust: lower than 83% of companies Debt: 0.0% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.00 (down more than 99.9%), Enliven Therapeutics, Inc. would be worth roughly what it owes.
Total debt $1.5M against a stock market value of $3.04B.
Distance to default 10.59 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $1.1M (short-term plus half of long-term), stock volatility 73.1%; Altman Z'' 66.56. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.00 (down more than 99.9%), Enliven Therapeutics, Inc. would be worth roughly what it owes.
Total debt $1.5M against a stock market value of $3.04B.
Distance to default 10.59 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $1.1M (short-term plus half of long-term), stock volatility 73.1%; Altman Z'' 66.56. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$3.0B
52W Range14.785-62.32
Volume2,323,029
Avg Volume1,337,374
Beta0.24
Dividend—
Analyst Ratings
Company Info
CEORichard A. Fair
Employees67
SectorHealthcare
IndustryBiotechnology
IPO Date2020-03-12
Websiteenliventherapeutics.com
6200 Lookout Road
Boulder, CO 80301
US
Boulder, CO 80301
US
720 647 8519
About Enliven Therapeutics, Inc.
Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.
Latest News
Brokers Issue Forecasts for ELVN FY2027 Earnings
Enliven, FDA agree on phase 3 trial design for relcobatinib for chronic myeloid leukemia
Enliven Therapeutics (NASDAQ:ELVN) Stock Falls 4.5% Following Insider Selling
Enliven Therapeutics (NASDAQ:ELVN) Director J. Scott Garland Sells 13,000 Shares of Company Stock
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives Average Recommendation of “Moderate Buy” from Brokerages
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Hohl Benjamin | M-Exempt | 6,018 | $14.85 | 2026-10-19 |
| Hohl Benjamin | S-Sale | 6,018 | $38.48 | 2026-10-19 |
| Hohl Benjamin | M-Exempt | 6,018 | $14.85 | 2026-10-19 |
| Collins Helen Louise | S-Sale | 5,000 | $38.47 | 2026-10-19 |
| BALL KRISTINE M | A-Award | 23,394 | $39.28 | 2026-10-14 |